 Kaustav Bera
Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Intelligence | 8 | 2024 | 245 | 2.910 |
Why?
| | Radiology | 5 | 2024 | 159 | 1.470 |
Why?
| | Neoplasms | 6 | 2023 | 2454 | 1.150 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 12 | 2022 | 1050 | 1.120 |
Why?
| | Radiometry | 3 | 2021 | 48 | 0.930 |
Why?
| | Tomography, X-Ray Computed | 13 | 2024 | 2511 | 0.890 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2024 | 23 | 0.880 |
Why?
| | Medical Oncology | 3 | 2024 | 268 | 0.880 |
Why?
| | Lung Neoplasms | 12 | 2022 | 2344 | 0.840 |
Why?
| | Publications | 1 | 2023 | 41 | 0.830 |
Why?
| | Extracellular Fluid | 1 | 2022 | 31 | 0.800 |
Why?
| | Viscosity | 1 | 2022 | 90 | 0.780 |
Why?
| | Prostatic Neoplasms | 3 | 2025 | 999 | 0.760 |
Why?
| | Cell Movement | 5 | 2022 | 950 | 0.710 |
Why?
| | Diagnostic Imaging | 3 | 2023 | 326 | 0.700 |
Why?
| | Neoplasm Metastasis | 2 | 2022 | 610 | 0.700 |
Why?
| | Actomyosin | 4 | 2024 | 17 | 0.690 |
Why?
| | Pathology, Clinical | 1 | 2019 | 36 | 0.630 |
Why?
| | Machine Learning | 4 | 2021 | 441 | 0.580 |
Why?
| | Precision Medicine | 3 | 2024 | 385 | 0.570 |
Why?
| | Oropharyngeal Neoplasms | 3 | 2022 | 48 | 0.540 |
Why?
| | Glioblastoma | 4 | 2022 | 322 | 0.530 |
Why?
| | Prognosis | 18 | 2022 | 3773 | 0.490 |
Why?
| | Biomarkers, Tumor | 5 | 2022 | 1161 | 0.460 |
Why?
| | Image Processing, Computer-Assisted | 5 | 2025 | 739 | 0.460 |
Why?
| | Papillomavirus Infections | 3 | 2022 | 297 | 0.430 |
Why?
| | Magnetic Resonance Imaging | 9 | 2024 | 3397 | 0.410 |
Why?
| | Sodium-Hydrogen Exchangers | 2 | 2022 | 26 | 0.400 |
Why?
| | Head and Neck Neoplasms | 3 | 2022 | 544 | 0.390 |
Why?
| | Immunotherapy | 3 | 2022 | 596 | 0.380 |
Why?
| | Actins | 3 | 2022 | 410 | 0.370 |
Why?
| | Hippocratic Oath | 1 | 2011 | 3 | 0.360 |
Why?
| | Alphapapillomavirus | 2 | 2022 | 39 | 0.360 |
Why?
| | Prostate | 2 | 2024 | 173 | 0.360 |
Why?
| | Humans | 57 | 2025 | 129847 | 0.360 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2022 | 88 | 0.350 |
Why?
| | Retrospective Studies | 21 | 2024 | 14553 | 0.350 |
Why?
| | Image Interpretation, Computer-Assisted | 3 | 2021 | 252 | 0.330 |
Why?
| | Granuloma | 2 | 2021 | 90 | 0.320 |
Why?
| | Physicians | 2 | 2023 | 875 | 0.310 |
Why?
| | Neoplasm Staging | 6 | 2025 | 1282 | 0.300 |
Why?
| | Brain Neoplasms | 4 | 2022 | 1149 | 0.300 |
Why?
| | Cell Size | 2 | 2024 | 89 | 0.280 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7066 | 0.270 |
Why?
| | Aged | 19 | 2024 | 22107 | 0.270 |
Why?
| | Radiology Information Systems | 2 | 2024 | 28 | 0.270 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1514 | 0.260 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 3 | 2024 | 99 | 0.250 |
Why?
| | Survival Analysis | 4 | 2022 | 1271 | 0.250 |
Why?
| | Sodium-Hydrogen Exchanger 1 | 1 | 2024 | 3 | 0.230 |
Why?
| | Tomography, Spiral Computed | 1 | 2024 | 27 | 0.230 |
Why?
| | Middle Aged | 19 | 2024 | 31177 | 0.230 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2024 | 16 | 0.230 |
Why?
| | Receptors, Peptide | 1 | 2024 | 17 | 0.230 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 66 | 0.230 |
Why?
| | Pneumothorax | 1 | 2024 | 38 | 0.230 |
Why?
| | Chemoradiotherapy | 3 | 2022 | 208 | 0.220 |
Why?
| | Radiography | 2 | 2023 | 800 | 0.220 |
Why?
| | Radiation Exposure | 1 | 2024 | 45 | 0.220 |
Why?
| | Anesthesia, Local | 1 | 2024 | 16 | 0.220 |
Why?
| | Breast Neoplasms | 3 | 2022 | 2104 | 0.220 |
Why?
| | Image-Guided Biopsy | 1 | 2024 | 37 | 0.220 |
Why?
| | Adenocarcinoma | 2 | 2022 | 893 | 0.220 |
Why?
| | Radiopharmaceuticals | 1 | 2024 | 168 | 0.220 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 204 | 0.220 |
Why?
| | Physicians, Women | 1 | 2024 | 72 | 0.210 |
Why?
| | Myofibroblasts | 1 | 2025 | 121 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1327 | 0.210 |
Why?
| | Societies, Medical | 2 | 2025 | 759 | 0.210 |
Why?
| | Radiography, Thoracic | 1 | 2024 | 165 | 0.210 |
Why?
| | Computed Tomography Angiography | 1 | 2024 | 115 | 0.210 |
Why?
| | Cytoskeleton | 1 | 2024 | 184 | 0.210 |
Why?
| | Radiation Dosage | 1 | 2024 | 154 | 0.210 |
Why?
| | Elasticity | 1 | 2024 | 195 | 0.210 |
Why?
| | Stomach Neoplasms | 1 | 2024 | 97 | 0.210 |
Why?
| | Neuroendocrine Tumors | 1 | 2024 | 99 | 0.210 |
Why?
| | Prostate-Specific Antigen | 1 | 2024 | 160 | 0.210 |
Why?
| | Neoadjuvant Therapy | 3 | 2020 | 379 | 0.200 |
Why?
| | Actin-Related Protein 2-3 Complex | 1 | 2022 | 8 | 0.200 |
Why?
| | Traction | 1 | 2022 | 19 | 0.200 |
Why?
| | Chick Embryo | 1 | 2022 | 130 | 0.200 |
Why?
| | Radiography, Dual-Energy Scanned Projection | 1 | 2022 | 7 | 0.200 |
Why?
| | TRPV Cation Channels | 1 | 2022 | 37 | 0.200 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2024 | 121 | 0.190 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 212 | 0.190 |
Why?
| | Atrial Appendage | 1 | 2022 | 15 | 0.190 |
Why?
| | Lung | 3 | 2024 | 3940 | 0.190 |
Why?
| | Spheroids, Cellular | 1 | 2022 | 76 | 0.190 |
Why?
| | Male | 22 | 2025 | 63759 | 0.190 |
Why?
| | Mechanical Phenomena | 1 | 2022 | 84 | 0.190 |
Why?
| | Treatment Outcome | 6 | 2024 | 10241 | 0.190 |
Why?
| | Bile Duct Neoplasms | 1 | 2022 | 99 | 0.180 |
Why?
| | Deglutition Disorders | 1 | 2022 | 133 | 0.180 |
Why?
| | Genital Neoplasms, Female | 1 | 2022 | 82 | 0.170 |
Why?
| | Esophageal Neoplasms | 1 | 2024 | 297 | 0.170 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2021 | 86 | 0.170 |
Why?
| | Calcinosis | 1 | 2022 | 233 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 957 | 0.170 |
Why?
| | Hydrogels | 2 | 2024 | 646 | 0.170 |
Why?
| | Fibroblasts | 1 | 2025 | 954 | 0.160 |
Why?
| | Myosin Type II | 1 | 2019 | 16 | 0.160 |
Why?
| | Cell Nucleus | 2 | 2019 | 590 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2020 | 283 | 0.160 |
Why?
| | Crohn Disease | 1 | 2023 | 217 | 0.160 |
Why?
| | Female | 23 | 2024 | 68829 | 0.160 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 54 | 0.160 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 612 | 0.150 |
Why?
| | Rectal Neoplasms | 1 | 2020 | 134 | 0.150 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2018 | 20 | 0.150 |
Why?
| | Pneumonectomy | 1 | 2020 | 151 | 0.150 |
Why?
| | Zebrafish | 1 | 2022 | 460 | 0.150 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1686 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 232 | 0.140 |
Why?
| | Computational Biology | 1 | 2022 | 594 | 0.140 |
Why?
| | Multimodal Imaging | 1 | 2018 | 110 | 0.140 |
Why?
| | Biopsy | 1 | 2021 | 1089 | 0.140 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 796 | 0.140 |
Why?
| | Cell Proliferation | 1 | 2024 | 2378 | 0.140 |
Why?
| | Algorithms | 1 | 2024 | 1617 | 0.130 |
Why?
| | Papillomaviridae | 3 | 2022 | 112 | 0.130 |
Why?
| | Receptor, ErbB-2 | 1 | 2019 | 325 | 0.130 |
Why?
| | Severity of Illness Index | 1 | 2024 | 2739 | 0.130 |
Why?
| | Emergency Service, Hospital | 2 | 2024 | 1920 | 0.130 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 680 | 0.120 |
Why?
| | Adult | 13 | 2024 | 35634 | 0.120 |
Why?
| | Survival Rate | 4 | 2021 | 1872 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1201 | 0.120 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2021 | 377 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 628 | 0.110 |
Why?
| | Internship and Residency | 1 | 2023 | 1058 | 0.110 |
Why?
| | Tumor Microenvironment | 3 | 2022 | 627 | 0.100 |
Why?
| | Workflow | 2 | 2023 | 157 | 0.100 |
Why?
| | Lung Diseases | 1 | 2018 | 743 | 0.100 |
Why?
| | Cytodiagnosis | 2 | 2022 | 32 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1199 | 0.090 |
Why?
| | India | 1 | 2011 | 171 | 0.090 |
Why?
| | Hypoxia | 1 | 2018 | 1087 | 0.090 |
Why?
| | Risk Assessment | 1 | 2020 | 3269 | 0.090 |
Why?
| | United States | 5 | 2025 | 13913 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2008 | 0.080 |
Why?
| | ROC Curve | 2 | 2022 | 504 | 0.080 |
Why?
| | Mice | 2 | 2024 | 16983 | 0.080 |
Why?
| | Water | 2 | 2022 | 442 | 0.080 |
Why?
| | Animals | 4 | 2025 | 35409 | 0.080 |
Why?
| | Mutation | 1 | 2020 | 3706 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1847 | 0.080 |
Why?
| | Disease-Free Survival | 2 | 2021 | 647 | 0.080 |
Why?
| | Brain | 1 | 2021 | 2677 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4896 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 851 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2021 | 1434 | 0.060 |
Why?
| | Biomarkers | 3 | 2022 | 3971 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2024 | 140 | 0.060 |
Why?
| | Radiologists | 1 | 2024 | 41 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1951 | 0.060 |
Why?
| | Efficiency | 1 | 2024 | 92 | 0.060 |
Why?
| | Azacitidine | 1 | 2025 | 137 | 0.050 |
Why?
| | High-Throughput Screening Assays | 1 | 2025 | 139 | 0.050 |
Why?
| | Accreditation | 1 | 2023 | 80 | 0.050 |
Why?
| | Mechanotransduction, Cellular | 1 | 2024 | 111 | 0.050 |
Why?
| | Barium | 1 | 2022 | 28 | 0.050 |
Why?
| | Dimethylpolysiloxanes | 1 | 2022 | 9 | 0.050 |
Why?
| | Pathologists | 1 | 2022 | 17 | 0.050 |
Why?
| | Bevacizumab | 1 | 2023 | 128 | 0.050 |
Why?
| | Bile Ducts | 1 | 2022 | 68 | 0.050 |
Why?
| | Anisotropy | 1 | 2022 | 73 | 0.050 |
Why?
| | Fibrosis | 1 | 2025 | 526 | 0.050 |
Why?
| | Ileum | 1 | 2023 | 116 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2022 | 68 | 0.050 |
Why?
| | Speech | 1 | 2022 | 73 | 0.050 |
Why?
| | Ion Channels | 1 | 2022 | 133 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2024 | 483 | 0.050 |
Why?
| | Hematoxylin | 1 | 2021 | 6 | 0.050 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2021 | 10 | 0.050 |
Why?
| | Ventilators, Mechanical | 1 | 2021 | 56 | 0.050 |
Why?
| | Nomograms | 1 | 2021 | 47 | 0.050 |
Why?
| | Aortic Valve Stenosis | 1 | 2024 | 219 | 0.050 |
Why?
| | Adaptation, Physiological | 1 | 2024 | 521 | 0.040 |
Why?
| | Cohort Studies | 2 | 2022 | 5444 | 0.040 |
Why?
| | Prostatectomy | 1 | 2021 | 103 | 0.040 |
Why?
| | Language | 1 | 2023 | 283 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 207 | 0.040 |
Why?
| | Polymers | 1 | 2024 | 479 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2024 | 508 | 0.040 |
Why?
| | Nuclear Envelope | 1 | 2019 | 28 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 443 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2019 | 102 | 0.040 |
Why?
| | Cytoplasm | 1 | 2019 | 269 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2018 | 38 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 116 | 0.040 |
Why?
| | Pulmonary Artery | 1 | 2024 | 1097 | 0.040 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2019 | 175 | 0.040 |
Why?
| | Forecasting | 1 | 2020 | 361 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 649 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1597 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2025 | 4102 | 0.030 |
Why?
| | Risk Factors | 2 | 2022 | 9801 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3062 | 0.030 |
Why?
| | Clinical Competence | 1 | 2023 | 1020 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2023 | 903 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2022 | 1063 | 0.030 |
Why?
| | Calcium | 1 | 2022 | 1212 | 0.030 |
Why?
| | Homeostasis | 1 | 2019 | 605 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2628 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 900 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 4935 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1269 | 0.030 |
Why?
| | Young Adult | 2 | 2020 | 12467 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2024 | 5772 | 0.030 |
Why?
| | Genomics | 1 | 2018 | 716 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2024 | 2481 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3185 | 0.020 |
Why?
| | Infant | 1 | 2024 | 9018 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7158 | 0.020 |
Why?
| | Adolescent | 1 | 2018 | 20451 | 0.010 |
Why?
|
|
Bera's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|